ReviewThe Journal of physiology2026
Experimental models of cerebral small vessel disease: Physiological constraints, translational challenges and future directions.
Review in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cerebral small vessel disease (cSVD) is a chronic, progressive cerebrovascular disorder and the second most common cause of dementia after Alzheimer's disease. It accounts for approximately 20% of strokes, including a quarter of ischaemic strokes and nearly half of vascular dementias, representing a growing clinical and socio-economic burden in ageing populations. Despite its prevalence, mechanistic understanding remains limited and disease-modifying therapies are lacking. A major obstacle is the difficulty of interrogating disease progression in vivo, as the small calibre and deep location of affected vessels restrict assessment. Experimental modelling has therefore been central to advancing cSVD research. Rodent models have provided insight into vascular dysfunction, white matter injury and blood-brain barrier (BBB) impairment, but differ from humans in cerebrovascular anatomy, cellular composition and disease trajectory. Emerging in vitro approaches, including three-dimensional cultures and microfluidic systems incorporating human vascular cells, offer improved experimental control and translational relevance, yet struggle to capture the slow progression of cSVD and its comorbidities such as hypertension and ageing. Most models therefore isolate pathological features rather than reproducing the integrated physiology of disease. In this review, we critically evaluate current in vivo, in vitro and in silico models of cSVD, highlighting their strengths and limitations. We identify the glymphatic system and brain clearance as underexplored but potentially unifying pathways linking vascular dysfunction, perivascular-space enlargement and impaired fluid clearance. Incorporating glymphatic elements into advanced models may address key mechanistic gaps. Improving physiological fidelity in cSVD modelling will be essential for robust target identification and development of effective therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.